Article Details
Retrieved on: 2022-03-08 04:22:36
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The European Commission has granted an orphan drug status to Aytu BioPharma's AR101 (enzastaurin), an oral therapy for Ehlers-Danlos syndrome.
Article found on: ehlersdanlosnews.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here